Loading...
OTCM
ACUR
Market cap33kUSD
Jul 29, Last price  
0.00USD
1D
0.00%
Jan 2017
-99.93%
IPO
-100.00%
Name

Acura Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-12.12%
Revenues
0k
-100.00%
5,750,000838,0008,205,00006,404,00044,437,0003,835,0003,311,00020,466,0000123,000751,0008,587,0004,464,0002,966,000410,0002,657,0003,570,0001,563,0000
Net income
0k
P
-48,455,000-69,996,000-12,075,000-5,967,000-4,314,00014,474,000-15,835,000-12,707,00010,385,000-9,668,000-13,901,000-13,209,000-4,989,000-7,388,000-5,682,000-3,842,000-3,950,000-1,658,000-1,079,0000
CFO
0k
P
-16,085,000-9,493,000-5,527,000-5,383,00019,220,0004,191,000-5,203,000-6,480,00012,312,000-7,038,000-13,678,000-11,044,000-3,688,000-5,563,000-4,510,000-3,908,000-618,000-719,000-742,0000

Profile

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.
URL
http://acurapharm.com/
IPO date
Sep 12, 2000
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
328
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
0.05
-90.00%
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT